TASLY PHARMACEUTICAL
Tasly is pioneering the most aggressive paradigm shift in modern medicine: scientifically proving that the 5,000-year old medical practice of Modern Traditional Chinese Medicine (mTCM) – healing the body with pure, natural herbs, is as effective as treating it with chemical and synthetic drug compounds. This will fulfill an unmet clinical need for healthcare providers and patients alike by being able to treat serious diseases with chemical-free products, which could be a game changer in modern medicine.
TASLY PHARMACEUTICAL
Industry:
Biotechnology Pharmaceutical
Founded:
1994-01-01
Address:
Tianjin, Guangdong, China
Country:
China
Website Url:
http://www.taslyint.com
Total Employee:
10001+
Status:
Active
Contact:
+02226736290
Technology used in webpage:
Google Font API Content Delivery Network Facebook Conversion Tracking MediaElement.js Twitter Tweet Button Alibaba HiChina DNS LiveChat
Similar Organizations
Beacon Pharmaceuticals
Beacon Pharmaceuticals is a oncology company that manufactures generic drugs, biotech, hi-tech & conventional general products.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Purdue Pharma
Purdue Pharma L.P., a pharmaceutical company committed to improving patients' lives and serving the healthcare community.
Samjin Pharmaceutical
Samjin Pharmaceutical is a company that pioneeres a healthy life for human beings with a creative mind and advances for a prosperous future.
Current Advisors List
Current Employees Featured
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-07 | Zhangshang Tangyi | Tasly Pharmaceutical investment in Series C - Zhangshang Tangyi | 100 M USD |
| 2018-08-14 | Profusa | Tasly Pharmaceutical investment in Series C - Profusa | 45 M USD |
| 2018-06-29 | I-Mab Biopharma | Tasly Pharmaceutical investment in Series C - I-Mab Biopharma | 220 M USD |
| 2018-04-11 | Shuwen Biotech | Tasly Pharmaceutical investment in Series A - Shuwen Biotech | N/A |
| 2017-03-23 | I-Mab Biopharma | Tasly Pharmaceutical investment in Series B - I-Mab Biopharma | 150 M USD |
| 2017-03-22 | Xiaoyusan | Tasly Pharmaceutical investment in Series B - Xiaoyusan | 100 M CNY |
| 2017-01-03 | Ascletis | Tasly Pharmaceutical investment in Series B - Ascletis | 100 M USD |
| 2015-09-02 | Ascletis | Tasly Pharmaceutical investment in Series B - Ascletis | 35 M USD |
